	US 12,070,512 B2
	Targeted gas-filled microvesicles formulation
Philippe Bussat, Pers-Jussy (FR); and Anne Lassus, Carouge (CH)
Assigned to Bracco Suisse SA, Cadempino (CH)
Filed by Bracco Suisse SA, Cadempino (CH)
Filed on Jun. 21, 2021, as Appl. No. 17/352,773.
Application 17/352,773 is a continuation of application No. 16/867,685, filed on May 6, 2020, granted, now 11,071,792.
Application 16/867,685 is a continuation of application No. 15/536,393, granted, now 10,682,429, issued on Jun. 16, 2020, previously published as PCT/EP2015/080199, filed on Dec. 17, 2015.
Claims priority of application No. 14199057 (EP), filed on Dec. 18, 2014.
Prior Publication US 2021/0386872 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 49/22 (2006.01); A61B 8/08 (2006.01)

CPC A61K 49/223 (2013.01) [A61B 8/481 (2013.01)]

17 Claims

1. An aqueous suspension of gas-filled microvesicles, said gas-filled microvesicles comprising distearoyl-phosphatidyl-choline (DSPC), palmitic acid, DPPE-PEG5000, and a targeting ligand comprising a peptide having an amino acid sequence selected from AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO: 01), VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO: 02) or a combination thereof, said aqueous suspension further comprising a carbohydrate and a histidine at a concentration of from 1.5 mM to 20 mM such that the aqueous suspension is compatible with intravenous injection.